Reported Earlier, BioMarin Settles Global Yuviwel Dispute, Secures Up To 20% Sales Royalty
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S.
BioMarin settled a patent fight with another company about a medicine called Yuviwel, and will now earn money (royalties—a percentage of sales) from it instead of fighting in court. This shows the company found a way to make money from the medicine without spending more time and money on legal battles.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.